Condition: Malignant Ascites Caused by Advanced Solid Tumors · Sponsor: Beijing Geekgene Technology Co., LTD
A single-arm, single-center, open-label clinical study comprising three cohorts, evaluating the safety, preliminary efficacy, and pharmacokinetic/ pharmacodynamic (PK/PD) characteristics of autologous tumor-reactive T cells (GK02) derived from malignant ascites caused by advanced solid tumors. The trial initially plans to enroll 9 subjects with malignant ascites caused by advanced solid tumors.
This description comes directly from the study's public registry record.
Changsong Qi, MD, PhD · +86-13811394004 · changsongqi@bjmu.edu.cn
Xu Zhang, PhD · +86-13482323610 · zhangx@geekgene.cn
Always discuss trial participation with your own doctor first.
| Beijing GoBroad Hospital | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07378436